Clinical trials: Mental
Generalized Anxiety Disorder
Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
The purpose of this study is to evaluate the safety and efficacy of 2.5 mg and 10 mg vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
- Trial name
- NCT00731120
- Testing
- Vortioxetine
- Where
- 40 sites in United States
- Volunteers
- 457 people
- Sponsor
- Takeda
Erectile Dysfunction
Treatment of Erectile Dysfunction I
Randomized, placebo-controlled, double-blind, parallel design, Phase 3 study to evaluate the safety and efficacy of udenafil, an orally administered, potent and selective inhibitor of PDE-5 versus placebo for the treatment of…
- Trial name
- NCT01037244
- Testing
- Udenafil
- Where
- 36 sites in United States
- Volunteers
- 618 people
- Sponsor
- Warner Chilcott
Autism Spectrum Disorder
Computer-based Social Skills Training for Autism Spectrum Disorder
The primary objective of this study is to evaluate changes in subject performance on social skills assessments after engaging in a gaze-controlled video game that leverages ABA principles of learning, in comparison to an…
- Trial name
- NCT03672344
- Testing
- Lookware TM, Lookware TM Control Module
- Where
- 11 sites in United States
- Volunteers
- 54 people
- Sponsor
- BioStream Technologies, LLC
Huntington Disease
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
- Trial name
- NCT05358821
- Testing
- SAGE-718
- Where
- 14 sites in United States, Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Dementia With Lewy Bodies
Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study
This study seeks to evaluate the efficacy and safety of intepirdine (RVT-101) in patients with dementia with Lewy bodies.
- Trial name
- NCT02669433
- Testing
- RVT-101 35 mg, RVT-101 70 mg
- Where
- 65 sites in United States, Canada and 5 more
- Volunteers
- 484 people
- Sponsor
- Axovant Sciences Ltd.
Major Depressive Disorder
The Safety, Tolerability, and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Subjects
The Safety, Tolerability and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Male and Female Subjects
- Trial name
- NCT04591301
- Testing
- HEC113995 PA•H2O tablets
- Where
- China
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Dementia, Alzheimer's Disease
Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia
The purpose of this trial is to test the safety \& tolerability of intramuscular aripiprazole in acutely agitated patients diagnosed with Dementia.
- Trial name
- NCT00095719
- Testing
- Aripiprazole
- Where
- 14 sites in United States
- Volunteers
- 125 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17
The purpose of this study is to assess the safety and efficacy of SPD503 (Guanfacine hydrochloride) compared to placebo in the treatment of ADHD in children and adolescents aged 6-17
- Trial name
- NCT00152009
- Testing
- SPD503 (Guanfacine hydrochloride) (2 mg), SPD503 (3 mg), SPD503 (4 mg)
- Volunteers
- 345 people
- Sponsor
- Shire
Healthy
A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants
The purpose of this study is to assess the effects of strong cytochrome P450 (CYP) 3A4 inhibitors (Itraconazole and Clarithromycin), on pharmacokinetics (PK) (study of the way a drug enters and leaves the blood and tissues over…
- Trial name
- NCT02197884
- Testing
- JNJ-54861911, 25 mg, Itraconazole 200 mg, Clarithromycin 500 mg
- Where
- Belgium
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Mild Cognitive Impairment (MCI), Parkinson Disease (PD)
A Study of CST-2032 in Subjects With Cognitive Impairment
This study will evaluate the effects of CST-2032 when administered with pre-administered CST-107 on safety, tolerability, cognition, cerebral perfusion, and cerebral metabolism in patients with cognitive impairment.
- Trial name
- NCT05033912
- Sponsor
- CuraSen Therapeutics, Inc.
Obsessive-compulsive Disorders and Symptoms, Obsessive-Compulsive Disorder
An ERP-based Mobile Intervention as an Adjunctive Treatment for OCD
The objective of this feasibility study is to evaluate the feasibility, acceptability, and potential usefulness of the investigational device, a mobile software application (app) (OC Free) for treatment of OCD (contamination…
- Trial name
- NCT05166707
- Testing
- BIXINK OC Free
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- BIXINK Therapeutics Co., Ltd.
Alzheimer's Disease
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 18 months.
- Trial name
- STEADFAST (NCT02080364)
- Testing
- Azeliragon
- Where
- 115 sites in United States, Australia and 5 more
- Volunteers
- 880 people
- Sponsor
- vTv Therapeutics
Substance Dependence
Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809
GSK598809 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders.
- Trial name
- NCT00437632
- Testing
- GSK598809, Caffeine
- Where
- United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Posttraumatic Stress Disorder
Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel
The goal of this clinical trial is to learn if MDMA-assisted therapy can treat PTSD in participants with PTSD. Researchers will compare two sessions of MDMA-assisted therapy with two sessions of low dose (active placebo)…
- Trial name
- NCT00402298
- Testing
- Full Dose Midomafetamine HCl, Low Dose Midomafetamine HCl
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- Resilient Pharmaceuticals
Erectile Dysfunction
Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction
An open-label investigation using MED3000 gel or tadalafil (5 mg) tablets in the treatment of erectile dysfunction in patients from 22 to 70 years of age. Each patients will be expected to participate for up to 30 weeks.
- Trial name
- NCT04984993
- Testing
- MED3000 (Male), Tadalafil 5mg (Male), MED3000 (Female)
- Where
- 18 sites in United States, Bulgaria and 2 more
- Volunteers
- 116 people
- Sponsor
- Futura Medical Developments Ltd.
Mental Health Disorder, Obesity
Improving Mental Health in Youth and Lowering Risk for Obesity Through a Digital Preventative Product
The goal of this study is to test the feasibility and utilization of a redesigned mobile app and health coaching platform (Vira) in youth (aged 18-25 years) with elevated depressive symptoms who are overweight/obese and/or…
- Conditions
- Mental Health Disorder, Obesity, Overweight
- Trial name
- NCT05638516
- Testing
- Vira mobile app intervention, Vira mobile app intervention + coaching
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Ksana Health
Alzheimer's Disease
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
The purpose of the study is to investigate the effect of bepranemab versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's Disease…
- Trial name
- NCT04867616
- Testing
- Bepranemab
- Where
- 103 sites in United States, Belgium and 8 more
- Volunteers
- 466 people
- Sponsor
- UCB Biopharma SRL
Alzheimer's Disease
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension.
- Trial name
- NCT07094516
- Testing
- VHB937
- Where
- 73 sites in United States, Australia and 13 more
- Volunteers
- 97 people
- Sponsor
- Novartis Pharmaceuticals
Adolescent Well-Being, Mental Health Wellness
Predict the Best Level of Care Placement for Each Child's Behavioral Health Needs - Effectiveness Study
The purpose of this study is to test the effectiveness of a new clinical decision support tool, Placement Success Predictor (PSP), in a naturalistic setting.
- Trial name
- NCT06834763
- Testing
- Clinical team access to Placement Success Predictor (PSP) results
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- Outcome Referrals, Inc.
Depressive Disorder
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in…
- Trial name
- NCT00250614
- Testing
- Saredutant succinate (SR48968C)
- Where
- United States
- Volunteers
- 452 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.